Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 11/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | PRKCA | P17252 | 2/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2770405 | 1.00 | SLC6A2 (0.38) | SLC6A2SLC6A3KMT2ATDP1ABCB1 | |
| SCHEMBL2767887 | 0.79 | ALDH1A1 (0.45) | SLC6A2SLC6A3KMT2ATDP1LMNA | |
| SCHEMBL7832703 | 0.78 | KMT2A (0.37) | SLC6A2SLC6A3KMT2ATDP1ABCB1 | |
| SCHEMBL20444761 | 0.75 | ABCB1 (0.46) | KMT2AABCB1 | |
| SCHEMBL25435703 | 0.75 | ALDH1A1 (0.36) | KMT2ALMNAALDH1A1PRKCABCHE | |
| SCHEMBL19492149 | 0.75 | ALDH1A1 (0.36) | KMT2ALMNAALDH1A1PRKCABCHE | |
| SCHEMBL12306528 | 0.74 | ALDH1A1 (0.37) | KMT2AABCB1LMNAALDH1A1PRKCA | |
| SCHEMBL30689540 | 0.74 | ALDH1A1 (0.35) | LMNAALDH1A1PRKCABCHECYP2D6 | |
| SCHEMBL20960060 | 0.73 | ALDH1A1 (0.43) | KMT2ALMNAALDH1A1BCHECYP2D6 | |
| SCHEMBL2718172 | 0.72 | GSTP1 (0.35) | LMNAALDH1A1BCHECYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1161439-B1 | XYLO-LNA ANALOGUES | EXIQON AS (DK) | 2010-04-21 | — | — | EP | disclosed |
| EP-1178999-B1 | L-RIBO-LNA ANALOGUES | SANTARIS PHARMA AS (DK) | 2007-03-14 | — | — | EP | disclosed |
| US-7084125-B2 | Xylo-LNA analogues | EXIQON A/S (DK) | 2006-08-01 | — | — | US | disclosed |
| US-7053207-B2 | L-ribo-LNA analogues | EXIQON A/S (DK) | 2006-05-30 | — | — | US | disclosed |
| US-20030087230-A1 | L-Ribo-LNA analogues | SANTARIS PHARMA A/S (DK) | 2003-05-08 | — | — | US | disclosed |
| US-20030082807-A1 | Xylo-LNA analogues | QIAGEN GMBH (DE) | 2003-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087230-A1 | L-Ribo-LNA analogues | RNGTT, NCL, RNASEL | SLC6A2 2077/4885SLC6A3 2601/4885KMT2A 1361/4885 |
| US-20030082807-A1 | Xylo-LNA analogues | FBL, NSUN2, RNGTT | SLC6A2 1543/4885SLC6A3 2422/4885KMT2A 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.